FLORHAM PARK, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2020 and provided an update of its ongoing pivotal Phase 3 trials for vonoprazan.

Go here to see the original:
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials

NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2020, and provided an update on the Company’s recent corporate developments.

View post:
Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20

See the original post:
Histogen Reports Third Quarter 2020 Earnings and Provides Business Update

TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020. These representatives of the company will host a presentation beginning at 3:30 p.m. ET.

Read the rest here:
Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announces details of its forthcoming Annual General Meeting (“the Meeting”) of shareholders. The Meeting will be held at the offices of Marcum LLP, 555 Long Wharf Dr. 8th floor, New Haven, CT 06511, USA, on Thursday December 10, 2020 at 9:00 a.m. (Eastern standard time).

See original here:
Bioasis Announces Annual General Meeting Details

- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2 Trials Using SCS Microinjector® Ongoing by Gene Therapy and Oncology Partners -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET -

More:
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Company to host conference call and webcast today, November 10, at 4:30pm ET Company to host conference call and webcast today, November 10, at 4:30pm ET

See the original post here:
Eyenovia Reports Third Quarter 2020 Financial Results

PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020.

See original here:
10x Genomics Reports Third Quarter 2020 Financial Results

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2020.

Link:
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products.

Read more:
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology...

Company to host investor conference call and webcast today at 5:00 pm EST Company to host investor conference call and webcast today at 5:00 pm EST

See the original post here:
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights

BOULDER, Colo., Nov. 10, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a biotechnology company advancing new treatments for patients with diseases that are underserved by current therapies, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates.

Link:
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

BRIDGEWATER, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of colorectal cancer diagnostic solutions, including liquid biopsy tests, today announced that Betsy Hanna, Chief Executive Officer, will present at the 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum as follows:

Read more here:
Clinical Genomics to Present at 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the third quarter of 2020.

Excerpt from:
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer is scheduled to present at the Jefferies Virtual London Healthcare Conference.

Originally posted here:
Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will present a company overview at the Jefferies Virtual London Healthcare Conference on Nov. 18.

Excerpt from:
Turning Point Therapeutics to Participate in Jefferies Virtual London Healthcare Conference

FOSTER CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will present at the Jefferies Virtual London Healthcare Conference on Tuesday November 17, 2020 at 12:35pm ET.

Visit link:
Vaxcyte to Present at Jefferies Virtual London Healthcare Conference

TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, will announce its financial results for the third quarter ended September 30, 2020, on Thursday, November 19, 2020 after market close. All figures in USD unless otherwise noted.

Follow this link:
Golden Leaf Holdings to Report Third Quarter Earnings

Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly

See the original post here:
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date

View original post here:
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease